PS1425 RESULTS OF THE DARATUMUMAB MONOTHERAPY EARLY ACCESS TREATMENT PROTOCOL (EAP) IN PATIENTS FROM EUROPE AND RUSSIA WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Gary Cook(Guy's Hospital), María‐Victoria Mateos(Hospital Clínico San Carlos), Eyt Chan(Janssen (United Kingdom)), Adrían Alegre(Hospital Universitario de La Princesa), MT Petrucci(Sapienza University of Rome), Huiling Pei(Janssen (United States)), Л. П. Менделеева(National Research Center for Hematology Russian Academy of Medical Sciences), Matthew Streetly(King's College - North Carolina), В. В. Птушкин(City Clinical Hospital), Assem Al-Akabawi(Janssen (United Kingdom)), Wafae Iraqi(Janssen (Belgium)), Cathrine Couturier(Brighton and Sussex Medical School), Alessandro Corso(Aziende Socio Sanitarie Territoriale Ovest Milanese), Maren Gaudig(Janssen (Germany))
Cited by 3
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
|Journal of Clinical Oncology|1998|563